Swedish Health Services

CommonSpirit Health Names Market President for the Greater Denver Market

Retrieved on: 
Thursday, April 4, 2024
Master of Science, Growth, CommonSpirit Health, St. Anthony Hospital, St. Elizabeth Hospital, Trinity University, Hospital, Rose Medical Center, Swedish Health Services, HCA Healthcare, Memorial Hermann Health System, Business administration, Longmont United Hospital, Nursing

CENTENNIAL, COLO., April 04, 2024 (GLOBE NEWSWIRE) -- CommonSpirit Health’s Mountain Region is pleased to announce that Ryan Tobin has been selected to serve as Market President for the Greater Denver Market.

Key Points: 
  • CENTENNIAL, COLO., April 04, 2024 (GLOBE NEWSWIRE) -- CommonSpirit Health’s Mountain Region is pleased to announce that Ryan Tobin has been selected to serve as Market President for the Greater Denver Market.
  • Ryan comes to CommonSpirit Health with considerable health care and leadership experience.
  • He previously served at HealthOne, part of HCA Healthcare, where he spent 12 years leading hospitals in the Denver market.
  • By applying his 16 years of leadership and Denver market knowledge, Ryan will help to ensure that the health system continues to provide high quality, compassionate care in its Greater Denver hospitals and ambulatory services.

Fujifilm Receives 510(k) Clearance for CAD EYE®, New AI-Powered Endoscopic Imaging Technology for Colonic Polyp Detection

Retrieved on: 
Wednesday, March 20, 2024
Colonoscopy, LCI, Documentation, Adenoma, EYE, Colorectal cancer, Conditional sentence, Risk, White Light, Polyp, APC, Assist, AI, Woman, Workflow, System, Safety, Swedish Health Services, Endoscopy, FDA, Health, CAD, Medical device

Lexington, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- FUJIFILM Healthcare Americas Corporation , a leading provider of endoscopic imaging and endosurgical solutions, received 510(k) clearance for CAD EYE, the company’s novel AI detection system for endoscopic imaging.

Key Points: 
  • Lexington, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- FUJIFILM Healthcare Americas Corporation , a leading provider of endoscopic imaging and endosurgical solutions, received 510(k) clearance for CAD EYE, the company’s novel AI detection system for endoscopic imaging.
  • CAD EYE® enables real-time detection of colonic mucosal lesions such as polyps and adenomas during colonoscopy procedures, supporting endoscopists in their ability to detect and remove pre-cancerous lesions, regardless of size, shape and color.
  • Consisting of a compatible expansion unit (the Fujifilm EX-1) and endoscopy support software (EW10-EC02), CAD EYE is an evolution of Fujifilm’s ELUXEO® Endoscopic Imaging System, featuring AI image processing functionality customized for the integration with the system’s processor and the endoscope.
  • CAD EYE, ELUXEO and LCI are registered trademarks of FUJIFILM Corporation in various jurisdictions.

HCA Healthcare Names Dr. Monique Butler as President of Graduate Medical Education

Retrieved on: 
Tuesday, March 12, 2024
General Health, Surgery, Other Health, Hospitals, Health, GME, University, Growth, Communication, Business, Business administration, Wayne State University, HCA, Accreditation, Hospital, History, Faculty, Sinai-Grace Hospital, Butler, Detroit Receiving Hospital, University of Tennessee, Swedish Health Services, HCA Healthcare, Multimedia, Graduate medical education, Physician, Movement

HCA Healthcare, Inc. (NYSE:HCA), one of the nation’s leading healthcare providers, today announced that Dr. Monique Butler has been appointed president of Graduate Medical Education, effective March 1, 2024.

Key Points: 
  • HCA Healthcare, Inc. (NYSE:HCA), one of the nation’s leading healthcare providers, today announced that Dr. Monique Butler has been appointed president of Graduate Medical Education, effective March 1, 2024.
  • Dr. Butler succeeds Dr. Bruce Deighton who will retire from HCA Healthcare later in 2024.
  • “Dr.
  • Dr. Butler joined HCA Healthcare in 2018 as the chief medical officer of Swedish Medical Center.

ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis

Retrieved on: 
Monday, March 11, 2024
MACR, Psoriatic arthritis, 1991 World Sportscar Championship, INC, Doctor of Philosophy, LOS, MD, SLRN, ISR, Rheumatology, Skin, Safety, Joint, Swedish Health Services, Enthesitis, Patient, Medicine, HS, LEI, Phase, IL-17A

LOS ANGELES, March 11, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced its global Phase 2b/3 clinical trial of izokibep in psoriatic arthritis (PsA) met the primary endpoint of ACR50 at week 16 with high statistical significance. Results from the 160 mg weekly (QW) and every other week (Q2W) arms showed improved magnitude of responses on higher hurdle endpoints such as ACR70, PASI100, and Minimal Disease Activity relative to the Phase 2 80 mg Q2W dose. This is notable given a higher baseline disease burden in the Phase 2b/3 trial population relative to the Phase 2 trial.

Key Points: 
  • (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced its global Phase 2b/3 clinical trial of izokibep in psoriatic arthritis (PsA) met the primary endpoint of ACR50 at week 16 with high statistical significance.
  • This is notable given a higher baseline disease burden in the Phase 2b/3 trial population relative to the Phase 2 trial.
  • Izokibep was well-tolerated with a favorable safety profile consistent with previous experience and the IL-17A class, without evidence of the safety liabilities observed with targeting IL-17A&F.
  • This reinforces our enthusiasm for developing izokibep as an important potential new medicine for patients.”

54 HCA Healthcare Hospitals Recognized as “America’s Best Hospitals” by Healthgrades

Retrieved on: 
Wednesday, January 31, 2024
General Health, Other Health, Hospitals, Health, Managed Care, Mortality, Rose Medical Center, Hospital, Medical Center, Wesley Medical Center, Swedish Health Services, HCA, CMS, Sky Ridge Medical Center, HCA Healthcare, HCA Florida Kendall Hospital, Medicare, Nursing

HCA Healthcare, Inc. (NYSE:HCA), one of the nation’s leading healthcare providers, today announced that 54 of its hospitals were recognized on the 2024 Healthgrades America’s 250 Best Hospitals list for superior performance in providing care for conditions and procedures across multiple specialty lines and areas.

Key Points: 
  • HCA Healthcare, Inc. (NYSE:HCA), one of the nation’s leading healthcare providers, today announced that 54 of its hospitals were recognized on the 2024 Healthgrades America’s 250 Best Hospitals list for superior performance in providing care for conditions and procedures across multiple specialty lines and areas.
  • “We strive for the highest standards of patient care,” said Dr. Michael Cuffe, executive vice president and chief clinical officer of HCA Healthcare.
  • In addition to Healthgrades’ 250 Best Hospitals list, a small percentage of hospitals are recognized for consistently delivering clinical excellence year over year in America’s 100 Best Hospitals and America’s 50 Best Hospitals lists.
  • Hospitals that have received an America’s 250 Best Hospitals Award consecutively over an extended period of time are evaluated by their tenure on the list and their current year’s performance to determine Healthgrades’ top 1% and 2% of hospitals list.

New Real-World Data Show TREMFYA® (guselkumab) Was Associated With Clinically Meaningful Improvements in Patient-Reported Outcomes for Adults Living With Active Psoriatic Arthritis

Retrieved on: 
Wednesday, November 8, 2023
St. Joseph's Health Centre, COSMOS, American College, Swedish Health Services, Psoriatic arthritis, University of Washington, Participation, SPRING, Disease, Visual analogue scale, HOUSE, Janssen Pharmaceuticals, University, American College of Rheumatology, Pain, Johnson & Johnson, Patient, ACR, Arthritis, Fatigue, Nursing, Pharmaceutical industry, Birth control

SPRING HOUSE, Pa., Nov. 8, 2023 /PRNewswire/ -- Janssen Pharmaceuticals, Inc., a Johnson & Johnson company, today announced new data from the CorEvitas Psoriatic Arthritis (PsA) and Spondyloarthritis Registry that showed a substantial proportion of people living with treatment-resistant active PsA and using TREMFYA® (guselkumab) in real-world settings reported meaningful improvements in pain, physical function and fatigue through six months.1 Additionally, across the DISCOVER-1, DISCOVER-2 and COSMOS clinical trials, treatment with TREMFYA was associated with higher rates of clinically meaningful improvements in a composite assessment of patient-reported pain, fatigue, physical function, skin problems and PsA-related depression than placebo in the first assessment of the PsA 5-Thermometer Scale Domains (PsA-5T-Ds).2

Key Points: 
  • "People living with active psoriatic arthritis who are treatment-resistant need options that improve debilitating symptoms of their disease, like pain, physical function and fatigue," said Philip Mease, M.D., Swedish Medical Center/Providence St. Joseph Health and University of Washington in Seattle, Washington.a "It is important that we assess patient-reported outcomes in a real-world setting, ensuring that we address unmet needs for people living with this challenging disease."
  • "It is critical that we evaluate patient-reported outcomes to truly understand the lived experiences of patients and better develop and provide treatments in psoriatic disease."
  • Dr. Philip Mease is a paid consultant for Janssen.
  • He has not been compensated for any media work.

Icertis Appoints Allan Golston to Board of Directors

Retrieved on: 
Wednesday, October 18, 2023
Cloud, University of Colorado Denver School of Public Affairs, Education, Azure, ICI, Committee on Finance, Microsoft, Seattle University, Social responsibility, Bill & Melinda Gates Foundation, Golston, MBA, Bill, National Medal of Technology and Innovation, Committee, Stryker Corporation, Trust, Growth, Icertis, Swedish Health Services, Compensation, Economic mobility, Microsoft Azure, Harley-Davidson, University, Health, Melinda French Gates, KPMG, CLM, University of Colorado Hospital, Audit, Commerce, Management

BELLEVUE, Wash., Oct. 18, 2023 /PRNewswire/ -- Icertis today announced that Allan Golston, President of the U.S. Program for the Bill & Melinda Gates Foundation, has joined its Board of Directors to support the company's purpose of building trust, strengthening bonds, and creating a better world through AI-powered contract intelligence. Golston also serves on the board of Stryker Corporation, where he acts as Chair of the Compensation and Human Capital Committee and a member of the Governance and Nominating Committee, as well as the board of Harley-Davidson, where he serves as Chair of the Nominating and Corporate Governance Committee and a member of the Audit and Finance Committee.

Key Points: 
  • BELLEVUE, Wash., Oct. 18, 2023 /PRNewswire/ -- Icertis today announced that Allan Golston, President of the U.S.
  • Program for the Bill & Melinda Gates Foundation, has joined its Board of Directors to support the company's purpose of building trust, strengthening bonds, and creating a better world through AI-powered contract intelligence.
  • Golston has played an instrumental role in the growth of the foundation since its founding in 2000 while also serving on the board of directors for a number of nonprofit, public, and private organizations.
  • Golston joins the board on the heels of a momentous quarter for Icertis, which included the launch of Icertis Contract Intelligence (ICI) Copilots – the market's first generative AI applications for enterprise contracting backed by the security of Microsoft Azure.

U.S. FDA Approves Pfizer’s VELSIPITY™ for Adults with Moderately to Severely Active Ulcerative Colitis (UC)

Retrieved on: 
Friday, October 13, 2023
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, Janus, United, NYSE, Food, UC, JAK, Proctitis, IBD, Inc., Mucus, Safety, Disease, Abdominal pain, Ulcerative colitis, Swedish Health Services, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Blood, Life, PFE, Pharmaceutical industry, Pfizer

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved VELSIPITY™ (etrasimod), an oral, once-daily, selective sphingosine-1-phosphate (S1P) receptor modulator for adults with moderately to severely active ulcerative colitis (UC).

Key Points: 
  • Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved VELSIPITY™ (etrasimod), an oral, once-daily, selective sphingosine-1-phosphate (S1P) receptor modulator for adults with moderately to severely active ulcerative colitis (UC).
  • Nearly two-thirds of patients in ELEVATE UC 52 and ELEVATE UC 12 were naïve to biologic or JAK inhibitor therapy, and these studies were also the only studies for advanced therapies for ulcerative colitis to include patients with isolated proctitis.
  • Both studies achieved all primary and key secondary efficacy endpoints, with a favorable safety profile consistent with previous studies of VELSIPITY.
  • “Because of the unpredictable nature of UC, people living with the disease can cycle through several different treatments over time.

FDA approves Novartis Cosentyx® as first intravenous (IV) formulation interleukin-17A antagonist for rheumatic diseases

Retrieved on: 
Friday, October 6, 2023
Psoriatic arthritis, Ankylosing spondylitis, Rheumatology Research Foundation, AS, Rheumatology, Swedish Medical Center (Colorado), University, Novartis, Medicine, US Foods, EAST, FDA, Swedish Health Services, IV, Research, University of Washington School of Medicine, Patient, Pharmaceutical industry, Secukinumab, Immunology

Cosentyx is the only treatment approved in an IV formulation that specifically targets and blocks interleukin-17A (IL-17A), and the only non-tumor necrosis factor alpha (TNF-α) IV option available in all these indications.

Key Points: 
  • Cosentyx is the only treatment approved in an IV formulation that specifically targets and blocks interleukin-17A (IL-17A), and the only non-tumor necrosis factor alpha (TNF-α) IV option available in all these indications.
  • The IV formulation of Cosentyx offers patients a monthly 30-minute, weight-based dosing option, requiring no pre-medication and no lab monitoring.1 The new IV administration option will be available in Q4 of 2023.
  • "The approval of Cosentyx as an IV formulation is an important milestone for patients because it expands the treatment options available to them with a different mechanism of action than existing biologic IV therapies, along with the comfort and familiarity of an established treatment."
  • "At Novartis, we are committed to ensuring healthcare providers and patients have treatment options available to meet their unique needs.

Marler Clark Files E. coli Lawsuit against Panera in Washington Federal Court

Retrieved on: 
Thursday, May 11, 2023
Cecum, CT, IV, Nation, United States district court, Pancolitis, Emergency department, Panera Bread, Escherichia coli, Colitis, Taylor Farms, Lettuce, CDC, Dysentery, Chronic pain, Swedish Health Services, Complaint, Genetic testing, FDA, Plaintiff, Farm, Poultry farming, Chipotle

SEATTLE, May 11, 2023 /PRNewswire/ -- An E. coli lawsuit was filed on behalf of Nicholas Lowe against Panera Bread in the Federal District Court of Washington.

Key Points: 
  • SEATTLE, May 11, 2023 /PRNewswire/ -- An E. coli lawsuit was filed on behalf of Nicholas Lowe against Panera Bread in the Federal District Court of Washington.
  • Mr. Lowe is represented by Marler Clark , the Nation's Food Safety Law Firm.
  • "Health authorities need to be transparent and companies like Panera and Taylor Farms need to be held accountable," added Marler.
  • A few days later, he began to develop symptoms consistent with E. coli O121:H19 including abdominal cramps and bloody diarrhea.